Literature DB >> 10458087

Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions.

T Sadayama1, S Miyagawa, T Shirai.   

Abstract

We report a 45-year-old female patient with dermatomyositis whose corticosteroid-resistant cutaneous manifestations improved with low-dose (0.1 g/kg body weight/day for 5 days weekly for 2 weeks) intravenous immunoglobulin (IVIG) therapy.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10458087     DOI： 10.1111/j.1346-8138.1999.tb02026.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


  6 in total

Review 1.  Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.

Authors:  Lyubomir A Dourmishev; Dimitrina V Guleva; Ljubka G Miteva
Journal:  Wien Med Wochenschr       Date:  2017-09-01

Review 2.  Idiopathic inflammatory myopathies: a treatment update.

Authors:  Chester V Oddis
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

Review 3.  Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.

Authors:  Hobart W Walling; Pedram Gerami; Richard D Sontheimer
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

Review 4.  Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment.

Authors:  Thorsten Hornung; Joerg Wenzel
Journal:  Drugs       Date:  2014-06       Impact factor: 11.431

5.  Paraneoplastic dermatomyositis presenting myopathy combined with synchronous cervical and sigmoid colon cancer.

Authors:  Jae Heun Chung; Min Wook So; Seong-Geun Kim
Journal:  Korean J Intern Med       Date:  2016-01-29       Impact factor: 2.884

Review 6.  Intravenous Immunoglobulins: Mode of Action and Indications in Autoimmune and Inflammatory Dermatoses.

Authors:  Lyubomir A Dourmishev; Dimitrina V Guleva; Ljubka G Miteva
Journal:  Int J Inflam       Date:  2016-01-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.